This company has been marked as potentially delisted and may not be actively trading.

Tocagen (TOCA) Competitors

TOCA vs. ZYME, MBX, CALT, AVTE, and LWAC

Should you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include Zymeworks (ZYME), MBX Biosciences (MBX), Calliditas Therapeutics AB (publ) (CALT), Aerovate Therapeutics (AVTE), and LightWave Acquisition (LWAC).

How does Tocagen compare to Zymeworks?

Zymeworks (NASDAQ:ZYME) and Tocagen (NASDAQ:TOCA) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

: Zymeworks presently has a consensus price target of $37.89, suggesting a potential upside of 42.01%. Given Zymeworks' stronger consensus rating and higher probable upside, equities analysts plainly believe Zymeworks is more favorable than Tocagen.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zymeworks
1 Sell rating(s)
1 Hold rating(s)

9 Buy rating(s)

2 Strong Buy rating(s)
2.92
Tocagen
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 92.9% of Zymeworks shares are held by institutional investors. Comparatively, 21.4% of Tocagen shares are held by institutional investors. 33.5% of Zymeworks shares are held by insiders. Comparatively, 10.9% of Tocagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Zymeworks has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Tocagen has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500.
: Tocagen has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zymeworks $105.96M 18.57 -$81.13M -$1.08 N/A
Tocagen $40K 15,708.80 -$63.52M -$2.69 N/A
: In the previous week, Zymeworks had 3 more articles in the media than Tocagen. MarketBeat recorded 3 mentions for Zymeworks and 0 mentions for Tocagen. Zymeworks' average media sentiment score of 0.45 beat Tocagen's score of 0.00 indicating that Zymeworks is being referred to more favorably in the media.
Company Overall Sentiment
Zymeworks Neutral
Tocagen Neutral
: Zymeworks has a net margin of -76.56% compared to Tocagen's net margin of -176,433.34%. Zymeworks' return on equity of -26.00% beat Tocagen's return on equity.
Company Net Margins Return on Equity Return on Assets
Zymeworks -76.56% -26.00% -20.57%
Tocagen -176,433.34% -327.74% -111.87%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92
Tocagen	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	18.57	-$81.13M	-$1.08	N/A
Tocagen	$40K	15,708.80	-$63.52M	-$2.69	N/A

Company	Overall Sentiment
Zymeworks	Neutral
Tocagen	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-76.56%	-26.00%	-20.57%
Tocagen	-176,433.34%	-327.74%	-111.87%

Summary

Zymeworks beats Tocagen on 14 of the 17 factors compared between the two stocks.

How does Tocagen compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Tocagen (NASDAQ:TOCA) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

: MBX Biosciences has a net margin of 0.00% compared to Tocagen's net margin of -176,433.34%. MBX Biosciences' return on equity of -28.72% beat Tocagen's return on equity.
Company Net Margins Return on Equity Return on Assets
MBX Biosciences N/A -28.72% -27.55%
Tocagen -176,433.34% -327.74% -111.87%
: MBX Biosciences currently has a consensus price target of $53.25, suggesting a potential upside of 79.90%. Given MBX Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe MBX Biosciences is more favorable than Tocagen.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MBX Biosciences
2 Sell rating(s)
0 Hold rating(s)

9 Buy rating(s)

1 Strong Buy rating(s)
2.75
Tocagen
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Tocagen has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MBX Biosciences N/A N/A -$86.97M -$2.41 N/A
Tocagen $40K 15,708.80 -$63.52M -$2.69 N/A
: 21.4% of Tocagen shares are owned by institutional investors. 10.9% of Tocagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
: MBX Biosciences has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Tocagen has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500.
: In the previous week, MBX Biosciences' average media sentiment score of 0.00 equaled Tocagen'saverage media sentiment score.
Company Overall Sentiment
MBX Biosciences Neutral
Tocagen Neutral

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-28.72%	-27.55%
Tocagen	-176,433.34%	-327.74%	-111.87%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Tocagen	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Tocagen	$40K	15,708.80	-$63.52M	-$2.69	N/A

Company	Overall Sentiment
MBX Biosciences	Neutral
Tocagen	Neutral

Summary

MBX Biosciences beats Tocagen on 9 of the 14 factors compared between the two stocks.

How does Tocagen compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Tocagen (NASDAQ:TOCA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

: Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Tocagen has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500.
: Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Tocagen's net margin of -176,433.34%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Tocagen's return on equity.
Company Net Margins Return on Equity Return on Assets
Calliditas Therapeutics AB (publ) -30.18% -212.04% -27.96%
Tocagen -176,433.34% -327.74% -111.87%
: Calliditas Therapeutics AB (publ) has higher revenue and earnings than Tocagen. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Calliditas Therapeutics AB (publ) $1.60B 0.74 -$43.96M -$1.85 N/A
Tocagen $40K 15,708.80 -$63.52M -$2.69 N/A
: In the previous week, Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Tocagen'saverage media sentiment score.
Company Overall Sentiment
Calliditas Therapeutics AB (publ) Neutral
Tocagen Neutral
: 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 21.4% of Tocagen shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 10.9% of Tocagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Tocagen	-176,433.34%	-327.74%	-111.87%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Tocagen	$40K	15,708.80	-$63.52M	-$2.69	N/A

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Tocagen	Neutral

Summary

Calliditas Therapeutics AB (publ) beats Tocagen on 7 of the 11 factors compared between the two stocks.

How does Tocagen compare to Aerovate Therapeutics?

Tocagen (NASDAQ:TOCA) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

: Tocagen has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.
: Aerovate Therapeutics has a net margin of 0.00% compared to Tocagen's net margin of -176,433.34%. Aerovate Therapeutics' return on equity of -90.19% beat Tocagen's return on equity.
Company Net Margins Return on Equity Return on Assets
Tocagen -176,433.34% -327.74% -111.87%
Aerovate Therapeutics N/A -90.19% -77.47%
: Tocagen has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tocagen $40K 15,708.80 -$63.52M -$2.69 N/A
Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A
: In the previous week, Aerovate Therapeutics had 1 more articles in the media than Tocagen. MarketBeat recorded 1 mentions for Aerovate Therapeutics and 0 mentions for Tocagen. Aerovate Therapeutics' average media sentiment score of 0.75 beat Tocagen's score of 0.00 indicating that Aerovate Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
Tocagen Neutral
Aerovate Therapeutics Positive
: 21.4% of Tocagen shares are owned by institutional investors. 10.9% of Tocagen shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Tocagen	-176,433.34%	-327.74%	-111.87%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tocagen	$40K	15,708.80	-$63.52M	-$2.69	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Company	Overall Sentiment
Tocagen	Neutral
Aerovate Therapeutics	Positive

Summary

Aerovate Therapeutics beats Tocagen on 9 of the 12 factors compared between the two stocks.

How does Tocagen compare to LightWave Acquisition?

LightWave Acquisition (NASDAQ:LWAC) and Tocagen (NASDAQ:TOCA) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

: LightWave Acquisition has higher earnings, but lower revenue than Tocagen.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LightWave Acquisition N/A N/A N/A N/A N/A
Tocagen $40K 15,708.80 -$63.52M -$2.69 N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LightWave Acquisition
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Tocagen
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, LightWave Acquisition's average media sentiment score of 0.00 equaled Tocagen'saverage media sentiment score.
Company Overall Sentiment
LightWave Acquisition Neutral
Tocagen Neutral
: 21.4% of Tocagen shares are held by institutional investors. 10.9% of Tocagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: LightWave Acquisition has a net margin of 0.00% compared to Tocagen's net margin of -176,433.34%. LightWave Acquisition's return on equity of 0.00% beat Tocagen's return on equity.
Company Net Margins Return on Equity Return on Assets
LightWave Acquisition N/A N/A N/A
Tocagen -176,433.34% -327.74% -111.87%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A
Tocagen	$40K	15,708.80	-$63.52M	-$2.69	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tocagen	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
LightWave Acquisition	Neutral
Tocagen	Neutral

Company	Net Margins	Return on Equity	Return on Assets
LightWave Acquisition	N/A	N/A	N/A
Tocagen	-176,433.34%	-327.74%	-111.87%

Summary

LightWave Acquisition beats Tocagen on 4 of the 7 factors compared between the two stocks.

Get Tocagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TOCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TOCA vs. The Competition

Export

Metric	Tocagen	Pharmaceutical Preparations Industry	Medical Sector	NASDAQ Exchange
Market Cap	$628.35M	$886.55M	$6.25B	$11.77B
Dividend Yield	N/A	4.84%	2.74%	5.26%
P/E Ratio	-11.08	0.96	24.91	23.23
Price / Sales	15,708.80	120.65	504.56	75.49
Price / Cash	N/A	20.07	43.30	53.90
Price / Book	58.38	7.60	9.67	6.69
Net Income	-$63.52M	-$4.80M	$3.55B	$332.64M

Tocagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TOCA Tocagen	N/A	$26.27 +0.4%	N/A	N/A	$628.35M	$40K	N/A	77	Gap Up
ZYME Zymeworks	2.4825 of 5 stars	$26.61 -3.4%	$37.89 +42.4%	N/A	$1.96B	$105.96M	N/A	460	Upcoming Earnings
MBX MBX Biosciences	2.3654 of 5 stars	$29.78 -1.5%	$53.25 +78.8%	N/A	$1.42B	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
AVTE Aerovate Therapeutics	N/A	$24.40 +9.3%	N/A	N/A	$707.23M	N/A	N/A	20	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TOCA) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tocagen (TOCA) Competitors

TOCA vs. ZYME, MBX, CALT, AVTE, and LWAC

How does Tocagen compare to Zymeworks?

Summary

How does Tocagen compare to MBX Biosciences?

Summary

How does Tocagen compare to Calliditas Therapeutics AB (publ)?

Summary

How does Tocagen compare to Aerovate Therapeutics?

Summary

How does Tocagen compare to LightWave Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOCA vs. The Competition

Tocagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tocagen (TOCA) Competitors

TOCA vs. ZYME, MBX, CALT, AVTE, and LWAC

How does Tocagen compare to Zymeworks?

Summary

How does Tocagen compare to MBX Biosciences?

Summary

How does Tocagen compare to Calliditas Therapeutics AB (publ)?

Summary

How does Tocagen compare to Aerovate Therapeutics?

Summary

How does Tocagen compare to LightWave Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOCA vs. The Competition

Tocagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools